About the project


Integrative structural biology of pathological tau protein, an appealing therapeutic target for Alzheimer's disease modifying drugs


We are aiming to:

  • establish a strong network of academic-industrial partners with cutting-edge, unique proprietary technologies and knowledge​
  • achieve scientific advancement in understanding the pathways of tau in neurodegeneration
  • adopt a unique panel of techniques and considering important interaction partners of pathologic tau
  • foster novel tools for neurodegeneration diagnostics and therapy


Project coordinator: 

• CEITEC MU (Czech Republic)


Project partners: 

• Institute of Neuroimmunology, Slovak Academy of Sciences (Slovakia) • Latvian Institute of Organic Synthesis (Latvia)

• Royal College of Surgeons (Ireland) • University of Pittsburgh (USA) • National University of Cuyo (Argentina)

• GENETON s.r.o. (Slovakia) • BioVendor - Laboratorní medicína (Czech Republic) • DATAMEDRIX GmbH (Austria) 

• Sanata Dharma University (Indonesia) • omiics ApS (Denmark)

Former project partners:

• Oregon State University (USA) • University Health Network (Canada) • AXON Neurosciences (Slovakia)







​Project duration: 66 months (01.01.2020 - 30.06.2025)
Project call: H2020-MSCA-RISE-2019
Total budget: 1 058 000 EUR


​This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 873127 – InterTAU.

This website reflects only the author's view and the Research Executive Agency (REA) is not responsible for any use that may be made of the information it contains.